SR ONE CAPITAL MANAGEMENT, LP Q3 2024 Filing
Filed November 13, 2024
Portfolio Value
$498.7B
Holdings
11
Report Date
Q3 2024
Filing Type
13F-HR
All Holdings (11 positions)
| # | Stock | Shares | Value | % Portfolio | Type |
|---|---|---|---|---|---|
| 1 | ACLXArcellx, Inc. | 2,346,630 | $196.0B | 39.29% | |
| 2 | ZBIOZenas BioPharma, Inc | 4,911,539 | $83.1B | 16.66% | |
| 3 | SPRYARS Pharmaceuticals, Inc. | 4,012,903 | $58.2B | 11.67% | |
| 4 | CRSPCRISPR Therapeutics AG | 1,048,951 | $49.3B | 9.88% | |
| 5 | DSGNDesign Therapeutics, Inc. | 6,526,476 | $35.1B | 7.04% | |
| 6 | MLYSMineralys Therapeutics Inc. | 2,016,822 | $24.4B | 4.90% | |
| 7 | ALMSAlumis Inc. | 1,959,896 | $20.9B | 4.20% | |
| 8 | NKTXNkarta, Inc. | 3,333,333 | $15.1B | 3.02% | |
| 9 | ORKAOruka Therapeutics, Inc | 375,330 | $9.2B | 1.84% | |
| 10 | ENGNenGene Holdings Inc. | 747,750 | $4.9B | 0.99% | |
| 11 | KALAKALA Bio, Inc. | 443,661 | $2.5B | 0.51% |